截至2025年5月20日 09:37，中证港股通医药卫生综合指数(930965)强势上涨3.03%，石药集团(01093)上涨6.90%，先声药业(02096)上涨6.67%，康哲药业 (00867)，诺诚健华(09969)等个股跟涨。 港股医药ETF(159718)上涨3.10%， 冲击3连涨。最新价报0.73元。拉长时间看，截至2025年5月19日，港股医药ETF近1周累计上涨3.50%。 截至2025年5月20日 09:37，中证医药及医疗器械创新指数(931484)强势上涨1.33%，成分股华海药业(600521)上涨10.00%，川宁生物(301301)上涨5.37%，科 伦药业(002422)上涨4.78%，神州细胞(688520)，智飞生物(300122)等个股跟涨。医疗创新ETF(516820)上涨0.87%，最新价报0.35元。拉长时间看，截至2025 年5月19日，医疗创新ETF近1周累计上涨1.48%。 流动性方面，医疗创新ETF盘中换手0.76%，成交1194.23万元。拉长时间看，截至5月19日，医疗创新ETF近1年日均成交4774.83万元。 流动性方面，港股医药ETF盘中换手4. ...

5月19日，南方中证全指医疗保健设备与服务ETF（159877）下跌0.04%，最新净值0.56元，连续4个交 易日下跌，区间累计跌幅1.34%。 来源：金融界 据了解，南方中证全指医疗保健设备与服务ETF成立于2021年10月，基金规模0.91亿元，成立来累计收 益率-44.22%。从持有人结构来看，截至2024年末，南方中证全指医疗保健设备与服务ETF的基金机构 持有0.16亿份，占总份额的10.95%，个人投资者持有0.92亿份，占总份额的63.55%。 公开信息显示，现任基金经理朱恒红先生:中国国籍,北京大学经济学硕士,具有基金从业资格。2016年7 月加入南方基金,历任数量化投资部助理研究员、指数投资部研究员;2019年7月12日至2020年12月25日, 任投资经理;2023年4月13日至2024年5月17日,任南方沪深300ESG基准ETF基金经理;2020年12月25日至 今,任南方策略基金经理;2021年4月23日至今,任南方中证创新药产业ETF基金经理;2021年7月16日至今, 任南方中证香港科技ETF(QDII)基金经理;2021年11月2日至今,任南方中证全指医疗保健ETF基金经 理 ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

Group 1 - The trend of Chinese medical device companies "going global" is long-term positive, especially in the upstream supply chain which has formed a certain scale [1] - In Q1 2025, China's medical device export trade total is projected to reach 69.26 billion yuan, a year-on-year increase of 5.03%, with high-end medical devices seeing significant growth [1] - The export value of China's medical device industry is expected to reach 48.75 billion USD in 2024, reflecting a year-on-year growth of 7.3% [1] Group 2 - Over 100 listed medical device companies have already initiated "going global" operations in 2024, covering various product areas such as medical consumables and diagnostic equipment [2] - Companies are advised to consider business, supply chain, and localization strategies for global expansion [2][3] - Localized production and supply chain management are essential for adapting to market demands in different regions [3] Group 3 - Companies like Haier Bio emphasize the importance of localizing product design and marketing to enhance user experience in overseas markets [4] - The trend of "going global" is common among mature, growth, and startup medical device companies, focusing on high-value and high-end products [6] - High-value medical devices, such as deep brain stimulators, require careful economic calculations and long-term service planning before entering foreign markets [6] Group 4 - Companies are encouraged to leverage digitalization and smart technologies to enhance their global strategies, as seen with Mindray Medical's remote monitoring capabilities [7] - Brand building is crucial for domestic medical device companies, with strategies including sponsorship of international sports events to enhance global influence [7] - The medical device market in Europe and the US accounts for over 65% of the global market share, making it a primary target for Chinese companies [8] Group 5 - Key conditions for Chinese medical device companies to "go global" include having sufficient capital, production capacity, and independent R&D capabilities [8] - Collaboration with local hospitals and doctors for joint R&D and clinical trials can facilitate product entry into new markets [8]

Market Performance - As of May 19, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) increased by 0.78%, with notable gains from companies such as Sihuan Pharmaceutical (02096) up 6.54% and 3SBio (01530) up 5.02% [1] - The Hong Kong Pharmaceutical ETF (159718) rose by 0.43%, with a latest price of 0.71 yuan, and has accumulated a 1.00% increase since the beginning of May [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) decreased by 0.57%, with Haisco Pharmaceutical (002653) leading gains at 5.04% [4] Liquidity and Trading Volume - The Hong Kong Pharmaceutical ETF had a turnover rate of 8.87% with a trading volume of 22.7183 million yuan, and an average daily trading volume of 84.1565 million yuan over the past month [1] - The Medical Innovation ETF (516820) had a turnover rate of 0.73% and a trading volume of 11.2970 million yuan, with an average daily trading volume of 47.7518 million yuan over the past year [4] Fund Size and Inflows - The Hong Kong Pharmaceutical ETF saw a significant increase in size, growing by 5.7693 million yuan over the past week, ranking 2nd among comparable funds [1] - The Medical Innovation ETF's latest size reached 1.563 billion yuan, with a financing buy-in amount of 3.0749 million yuan and a financing balance of 59.7821 million yuan [4] Industry Trends and Opportunities - The innovative drug industry is experiencing a convergence of policy, industry, and performance factors, indicating a potential new cycle of value reassessment [5] - Changes in commercial insurance directory policies and the upcoming data releases from major cancer conferences are expected to create further opportunities in innovative and some generic drugs [5] - The trend of domestic innovative drugs expanding overseas remains strong, with multiple business development transactions occurring despite recent tariff disruptions [5] Major Holdings - As of April 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including companies like BeiGene (06160) and WuXi Biologics (02269) [6] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, with major players such as Hengrui Medicine (600276) and WuXi AppTec (603259) [9]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as "Jianxin Superconducting") is pushing for an IPO on the Sci-Tech Innovation Board, with a global market share of approximately 4.2% in 2024, ranking fifth globally in the medical MRI core component supply sector [1][2]. Group 1: Company Performance - Jianxin Superconducting's revenue from 2022 to 2024 was 359 million yuan, 451 million yuan, and 425 million yuan respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [2][3]. - The company's gross profit margins for the same period were 19.56%, 22.84%, and 24.94%, significantly lower than the industry average of 46.27%, 45.59%, and 45.17% [3]. Group 2: Research and Development - Jianxin Superconducting's R&D expenses from 2022 to 2024 were 20.33 million yuan, 24.42 million yuan, and 27.65 million yuan, with R&D expense ratios of 5.66%, 5.42%, and 6.50% [3]. - The cumulative R&D investment over the last three years was 72.40 million yuan, accounting for 5.86% of total revenue [3]. Group 3: Customer Concentration - The company has a high customer concentration, with sales to the top five customers accounting for 73.75%, 76.68%, and 79.62% of total revenue in the respective years [4]. - The largest customer, Fujifilm Group, represented 34.2%, 44.2%, and 42.71% of sales revenue during the same period [4]. Group 4: Future Plans and Funding - Jianxin Superconducting plans to raise up to 865 million yuan through the IPO, primarily for capacity expansion and working capital [1][5]. - The company has consistently paid dividends, totaling approximately 60 million yuan from 2022 to 2024, with over half of this amount benefiting the controlling family [6].

Core Viewpoint - The article discusses the shift in trade dynamics between the U.S. and China, highlighting how China's response to U.S. tariffs has led to a reevaluation of its reliance on American products and a diversification of its supply chains [1][20]. Trade Relations - Following the imposition of tariffs by the Trump administration, U.S. farmers, particularly soybean and corn producers, are facing significant challenges due to reduced demand from China, leading to surplus stocks and plummeting prices [6][12]. - The article emphasizes that the previous dependency on U.S. agricultural imports has changed, with China now seeking alternative sources for its agricultural needs, such as Brazil for soybeans, which offers competitive pricing [13][14]. Supply Chain Adjustments - The narrative illustrates how China has learned from past market fluctuations and is now focused on building a more resilient and autonomous supply chain, reducing reliance on any single country [8][18]. - Companies in China are increasingly investing in domestic production capabilities, as seen with Huawei's chip development and the rise of local medical equipment manufacturers [11][18]. Global Market Strategy - China's strategy involves expanding its global partnerships and investments, particularly in South America, to enhance its procurement efficiency and reduce transportation costs [16][18]. - The article points out that the global supply chain landscape is evolving, with a greater emphasis on security and self-sufficiency, especially in critical sectors like technology and agriculture [18][19]. U.S. Market Dependency - Despite the U.S. attempts to reduce reliance on Chinese manufacturing, the article argues that many American products still depend on Chinese components, indicating the complexity of decoupling from China [19][20]. - The article concludes that the current international landscape is no longer dominated by a single country, and any nation's development is intertwined with China's role in the global economy [20].

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 156 yuan [1]. Core Insights - The company has experienced rapid growth overseas, with its overseas revenue reaching 2.266 billion yuan in 2024, a year-on-year increase of 35.07%, accounting for 22% of total revenue [6]. - Despite a decline in domestic revenue due to industry adjustments, the company has managed to increase its market share in China by over 3 percentage points [6]. - The maintenance service business has shown steady growth, with revenue increasing by 26.80% to 1.356 billion yuan, contributing to an overall gross margin improvement to 48.54% [6]. - The forecasted net profit for 2025-2027 is expected to be 1.885 billion, 2.288 billion, and 2.784 billion yuan respectively, with corresponding EPS of 2.29, 2.78, and 3.38 yuan [6]. Financial Performance Summary - Total revenue for 2024 is projected at 10.3 billion yuan, with a year-on-year decline of 9.7%. However, growth is expected to rebound with a forecasted increase of 20.5% in 2025 [2]. - The net profit for 2024 is estimated at 1.262 billion yuan, reflecting a significant year-on-year decrease of 36.1%, but a recovery is anticipated with a 49.3% increase in 2025 [2]. - The company’s price-to-earnings ratio is projected to decrease from 90 in 2024 to 41 by 2027, indicating an improving valuation over time [2]. Market Position and Strategy - The company has established a global marketing and service network covering over 85 countries and regions, with a team of more than 700 marketing personnel and over 1,000 service engineers [6]. - The company has successfully set up localized sales and service platforms in key markets such as the Netherlands, France, Italy, and Spain, enhancing its global footprint [6]. - The report highlights the structural opportunities arising from a large-scale medical equipment update policy initiated in 2024, which is expected to benefit the industry in the long term [6].

Group 1 - The Shanghai Composite Index fell by 0.40%, while the CSI Shanghai State-owned Enterprises Index decreased by 0.48%, closing at 1334.63 points with a trading volume of 14.95 billion [1] - The CSI Shanghai State-owned Enterprises Index has increased by 2.26% over the past month, decreased by 2.65% over the past three months, and has declined by 6.02% year-to-date [1] - The index reflects the overall performance of listed companies in Shanghai that are state-owned or significantly state-held, based on profitability, growth potential, and shareholder return levels [1] Group 2 - The top ten holdings in the CSI Shanghai State-owned Enterprises Index include China Pacific Insurance (8.59%), Shanghai Airport (6.25%), Guotai Junan Securities (5.57%), Shanghai Bank (5.54%), and others [1] - The index is composed entirely of companies listed on the Shanghai Stock Exchange, with a 100% representation [1] - The industry composition of the index shows that finance accounts for 29.83%, industrials for 23.33%, consumer discretionary for 12.42%, real estate for 9.62%, and healthcare for 7.17% [2] Group 3 - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Public funds tracking the Shanghai State-owned Enterprises Index include Huatai-PineBridge CSI Shanghai State-owned Enterprises ETF and its variants [2]

Core Insights - The aging population, scarcity of grassroots medical resources, and uneven distribution of quality medical resources are driving the rapid integration and application of AI technology in the healthcare sector [2] - AI medical technology is expected to reconstruct the medical value chain, creating a new model for equitable access to medical resources [5] - The domestic AI medical market is projected to reach 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [7] Industry Overview - The aging population in China is expected to reach 310 million by the end of 2024, accounting for 22% of the total population, and is projected to exceed 400 million by 2035, surpassing 30% [2] - Grassroots medical institutions account for 94.9% of all medical institutions in China but only handle 51.8% of the total medical services, indicating a mismatch in resource utilization and service quality [2] - AI technology is being rapidly integrated across various medical processes, including imaging diagnosis, surgical assistance, drug development, and intelligent management [2] AI Medical Technology - AI medical technology enhances the quality and efficiency of healthcare services by providing intelligent management and optimization of medical processes [3] - AI medical devices can be categorized into two types: those that include hardware (e.g., diagnostic analysis systems, robots) and those that operate as standalone software [3] - The advantages of AI in healthcare include high efficiency, accuracy, and low misdiagnosis rates, which can significantly improve diagnostic processes and treatment timelines [4] Market Potential - The AI medical market is expanding rapidly, with significant applications in drug and vaccine development, medical imaging analysis, smart hospital management, and genomics research [7] - AI applications in in-vitro diagnostics are expected to grow at a compound annual growth rate of 26.1% by 2028 [17] Company Profiles - Mindray Medical (300760) has a comprehensive product line in life information and support, in vitro diagnostics, and medical imaging, with a projected revenue of 36.725 billion yuan in 2024, a 5.14% increase year-on-year [10] - United Imaging (688271) focuses on medical imaging equipment and has been investing in AI since 2017, with a projected revenue of 10.3 billion yuan in 2024, a 9.73% decrease year-on-year [14] - BGI Genomics (300676) specializes in genomic testing services and is expected to generate 3.867 billion yuan in revenue in 2024, an 11.10% decrease year-on-year [19] - Yuyue Medical (002223) is a leading provider of medical devices, with a projected revenue of 7.566 billion yuan in 2024, a 5.09% decrease year-on-year [23] - Kefu Medical (301087) focuses on home medical devices and is expected to achieve 2.983 billion yuan in revenue in 2024, a 4.53% increase year-on-year [25]